Publications

Peer-reviewed work from our oncology programs — spatial omics, multiplex protein, and bulk transcriptomics across the drug-development pipeline.

Filter by

38 publications

Sep 2026 · Molecular Cancer

Identification of microenvironment features associated with primary resistance to anti-PD-1/PD-L1 + antiangiogenesis in gastric cancer through spatial transcriptomics and plasma proteomics

GastrointestinalBiomarker analysisBiomarker discoveryDiscoverypre/post studyTrialsFFPE tissuePlasmaGeoMx DSPMultiplex IFProteomics

Jul 2026 · Cancer Cell

GABA promotes resistance to immunotherapy in patients with TLS-positive tumors

Bone and soft tissueGenitourinaryBiomarker analysisBiomarker discoveryDiscoveryTarget discoveryTLS scoringTrialsB cellsFFPE tissueFresh-frozen tissueMouseMetabolomicsMultiplex IHCRNAseqVisium HD

Feb 2026 · Clinical Cancer Research

Adenosine A2B Receptor Promotes Tumor Progression and Metastases in Undifferentiated Pleomorphic Sarcoma

Bone and soft tissueBiomarker discoveryTarget discoveryFFPE tissueBioinformaticsGeoMx DSPMultiplex IF

Dec 2025 · Science Advances

Immune control of functional memory CD8 T cells in normal-appearing vitiligo skin

SkinBiomarker analysisDiscoveryTrialsFFPE tissueFresh-frozen tissueFlow cytometryMultiplex IFMultiplex IHCscRNAseq

Oct 2025 · Cancer Cell

Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer

BreastGenitourinarySkinBiomarker analysispre/post studyTLS scoringTrialsFFPE tissueMultiplex IF

Jun 2025 · Signal Transduction and Targeted Therapy

Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-angiogenics: a phase 2 trial of regorafenib combined with avelumab

Bone and soft tissueBiomarker analysispre/post studyTLS scoringTrialsFFPE tissueBioinformaticsMultiplex IFProteomics

Apr 2025 · Nature Cancer

Regorafenib plus avelumab in advanced gastroenteropancreatic neuroendocrine neoplasms: a phase 2 trial and correlative analysis

EndocrineGastrointestinalBiomarker analysisBiomarker discoveryDiscoveryTrialsFFPE tissuePlasmaBioinformaticsMetabolomicsMultiplex IHCProteomics

Feb 2025 · Cell Reports Medicine

Spatially resolved transcriptomics reveal the determinants of primary resistance to immunotherapy in NSCLC with mature tertiary lymphoid structures

ThoracicBiomarker analysisBiomarker discoveryDiscoveryTarget discoveryTLS scoringTrialsFFPE tissueBioinformaticsGeoMx DSPMultiplex IFMultiplex IHCRNAseq

Jul 2024 · OncoImmunology

Faecalibacterium prausnitzii strain EXL01 boosts efficacy of immune checkpoint inhibitors

Bone and soft tissueGastrointestinalSkinThoracicDC assaysPreclinical developmentT cell assaysMousePBMCCytokine analysisFlow cytometry

Feb 2024 · Molecular Cancer

Reshaping the tumor microenvironment of cold soft-tissue sarcomas with oncolytic viral therapy: a phase 2 trial of intratumoral JX-594 combined with avelumab and low-dose cyclophosphamide

Bone and soft tissueBiomarker analysispre/post studyTrialsFFPE tissuePlasmaMultiplex IFMultiplex IHCProteomics

Feb 2024 · Molecular Cancer

Impact of metronomic trabectedin combined with low-dose cyclophosphamide on sarcoma microenvironment and correlation with clinical outcome: results from the TARMIC study

Bone and soft tissueBiomarker analysispre/post studyTrialsFFPE tissueMultiplex IF

Nov 2023 · Cancer Research Communications

Antitumor Effects of PRMT5 Inhibition in Sarcomas

Bone and soft tissueDiscoveryTarget discoveryTumor cell linesBioinformaticsRNAseq

Sep 2023 · Clinical Cancer Research

Upregulation of Indoleamine 2,3-Dioxygenase 1 in Tumor Cells and Tertiary Lymphoid Structures is a Hallmark of Inflamed Non–Small Cell Lung Cancer

ThoracicB cell assaysBiomarker analysisBiomarker discoveryDiscoveryPreclinical developmentTLS scoringTrialsFFPE tissuePBMCBioinformaticsFlow cytometryGeoMx DSPMultiplex IFRNAseq

Jan 2023 · Laboratory Investigation

Standardized Pathology Screening of Mature Tertiary Lymphoid Structures in Cancers

Bone and soft tissueGastrointestinalBiomarker analysisTLS scoringTrialsFFPE tissueBioinformaticsMultiplex IF

Dec 2022 · Experimental Hematology & Oncology

Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer

BreastBiomarker analysispre/post studyTrialsPlasmaBioinformaticsProteomics

Oct 2022 · Journal of Hematology & Oncology

Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study

Bone and soft tissueBiomarker analysispre/post studyTLS scoringTrialsFFPE tissuePlasmaBioinformaticsMultiplex IFProteomics

Oct 2022 · Journal of Hematology & Oncology

Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma

Bone and soft tissueBiomarker analysispre/post studyTrialsPlasmaBioinformaticsProteomics

Jul 2022 · Annals of Oncology

Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors

Bone and soft tissueGastrointestinalGenitourinaryHead and neckSkinThoracicBiomarker analysisBiomarker discoveryDiscoveryPreclinical developmentT cell assaysTrialsFFPE tissueMousePBMCPlasmaBioinformaticsCytokine analysisFlow cytometryMetabolomicsMultiplex IF

Jun 2022 · Immunity

Indoleamine 2,3-dioxygenase 1 activation in mature cDC1 promotes tolerogenic education of inflammatory cDC2 via metabolic communication

DC assaysDiscoveryTarget discoveryPBMCPlasmaMetabolomicsMultiplex IF

May 2022 · Annals of Oncology

Impact of acetaminophen on the efficacy of immunotherapy in cancer patients

Bone and soft tissueGastrointestinalGenitourinarySkinThoracicBiomarker analysisBiomarker discoveryDiscoveryPreclinical developmentTrialsMousePBMCPlasmaBioinformaticsCytokine analysisFlow cytometryProteomics

May 2022 · Nature Medicine

Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort

Bone and soft tissueBiomarker analysisTLS scoringTrialsFFPE tissueBioinformaticsGeoMx DSPMultiplex IF

May 2022 · Journal for ImmunoTherapy of Cancer

Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies

ThoracicBiomarker analysisBiomarker discoveryDiscoverypre/post studyTrialsFFPE tissueBioinformaticsGeoMx DSP

Jan 2022 · Frontiers in Immunology

Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives

Bone and soft tissueBreastCentral nervous systemGastrointestinalGenitourinaryGynecologicHead and neckHematologicSkinThoracicBiomarker analysisBiomarker discoveryDiscoveryTarget discoveryTrials

Jan 2022 · Frontiers in Immunology

Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives

Biomarker analysisBiomarker discoveryDiscoveryTarget discoveryTrials

Jan 2022 · European Journal of Cancer

Regorafenib–avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial

GastrointestinalBiomarker analysispre/post studyTrialsFFPE tissueBioinformaticsMultiplex IFMultiplex IHC

Dec 2021 · Marine Drugs

Fucoidan Independently Enhances Activity in Human Immune Cells and Has a Cytostatic Effect on Prostate Cancer Cells in the Presence of Nivolumab

GenitourinaryPreclinical developmentT cell assaysTumor killing assaysImmune/tumor cell co-cultureLive-cell imaging

Dec 2021 · iScience

CD95/Fas suppresses NF-κB activation through recruitment of KPC2 in a CD95L/FasL-independent mechanism

BreastDiscoveryTarget discoveryImmune/tumor cell co-cultureBioinformatics

Nov 2021 · Clinical Cancer Research

Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study

Bone and soft tissueGynecologicBiomarker analysispre/post studyTrialsFFPE tissueBioinformaticsMultiplex IFMultiplex IHC

Nov 2021 · iScience

CD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells

BreastBiomarker discoveryDiscoveryPreclinical developmentTarget discoveryImmune/tumor cell co-cultureMouseBioinformaticsFlow cytometryMultiplex IHCRNAseq

Aug 2021 · Annals of Oncology

Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance

Bone and soft tissueBreastEndocrineGastrointestinalGenitourinaryGynecologicHead and neckSkinThoracicBiomarker analysisBiomarker discoveryDiscoverypre/post studyTarget discoveryTrialsFFPE tissuePlasmaBioinformaticsMultiplex IFMultiplex IHCProteomics

Aug 2021 · Nature Cancer

Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression

Bone and soft tissueBreastEndocrineGastrointestinalGenitourinaryGynecologicHead and neckThoracicBiomarker analysisBiomarker discoveryDiscoverypre/post studyTLS scoringTrialsFFPE tissueBioinformaticsMultiplex IFMultiplex IHC

Jan 2021 · Clinical Cancer Research

Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial

GastrointestinalBiomarker analysispre/post studyTrialsFFPE tissueBioinformaticsMultiplex IFMultiplex IHC

Jul 2020 · Biomarker Research

Inactivating mutations in genes encoding for components of the BAF/PBAF complex and immune-checkpoint inhibitor outcome

GenitourinaryGynecologicSkinBiomarker discoveryDiscoveryBioinformatics

Mar 2020 · Frontiers in Immunology

IDO Targeting in Sarcoma: Biological and Clinical Implications

Bone and soft tissueBiomarker analysisBiomarker discoveryDiscoveryPreclinical developmentFFPE tissueFresh-frozen tissueImmune/tumor cell co-cultureMousePlasmaBioinformaticsFlow cytometryMetabolomicsMultiplex IHCRNAseq

Feb 2020 · The Lancet Oncology

Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial

Bone and soft tissueBiomarker analysisTrialsPlasmaProteomics

Nov 2018 · Nature Communications

Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma

SkinBiomarker discoveryDiscoveryTarget discoveryImmune/tumor cell co-cultureMouseRNAseq

Jun 2017 · JAMA Oncology

Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial

Bone and soft tissueBiomarker analysisTrialsFFPE tissuePlasmaMetabolomicsMultiplex IFMultiplex IHC

Apr 2015 · PLOS ONE

Accumulation of an Endogenous Tryptophan-Derived Metabolite in Colorectal and Breast Cancers

BreastGastrointestinalBiomarker analysisDiscoveryTarget validationFFPE tissueMultiplex IHC

No publications match those filters.

Publications

Peer-reviewed work from our oncology programs — spatial omics, multiplex protein, and bulk transcriptomics across the drug-development pipeline.

Identification of microenvironment features associated with primary resistance to anti-PD-1/PD-L1 + antiangiogenesis in gastric cancer through spatial transcriptomics and plasma proteomics

GABA promotes resistance to immunotherapy in patients with TLS-positive tumors

Adenosine A2B Receptor Promotes Tumor Progression and Metastases in Undifferentiated Pleomorphic Sarcoma

Immune control of functional memory CD8 T cells in normal-appearing vitiligo skin

Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer

Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-angiogenics: a phase 2 trial of regorafenib combined with avelumab

Regorafenib plus avelumab in advanced gastroenteropancreatic neuroendocrine neoplasms: a phase 2 trial and correlative analysis

Spatially resolved transcriptomics reveal the determinants of primary resistance to immunotherapy in NSCLC with mature tertiary lymphoid structures

Faecalibacterium prausnitzii strain EXL01 boosts efficacy of immune checkpoint inhibitors

Reshaping the tumor microenvironment of cold soft-tissue sarcomas with oncolytic viral therapy: a phase 2 trial of intratumoral JX-594 combined with avelumab and low-dose cyclophosphamide

Impact of metronomic trabectedin combined with low-dose cyclophosphamide on sarcoma microenvironment and correlation with clinical outcome: results from the TARMIC study

Antitumor Effects of PRMT5 Inhibition in Sarcomas

Upregulation of Indoleamine 2,3-Dioxygenase 1 in Tumor Cells and Tertiary Lymphoid Structures is a Hallmark of Inflamed Non–Small Cell Lung Cancer

Standardized Pathology Screening of Mature Tertiary Lymphoid Structures in Cancers

Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer

Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study

Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma

Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors

Indoleamine 2,3-dioxygenase 1 activation in mature cDC1 promotes tolerogenic education of inflammatory cDC2 via metabolic communication

Impact of acetaminophen on the efficacy of immunotherapy in cancer patients

Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort

Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies

Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives

Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives

Regorafenib–avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial

Fucoidan Independently Enhances Activity in Human Immune Cells and Has a Cytostatic Effect on Prostate Cancer Cells in the Presence of Nivolumab

CD95/Fas suppresses NF-κB activation through recruitment of KPC2 in a CD95L/FasL-independent mechanism

Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study

CD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells

Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance

Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression

Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial

Inactivating mutations in genes encoding for components of the BAF/PBAF complex and immune-checkpoint inhibitor outcome

IDO Targeting in Sarcoma: Biological and Clinical Implications

Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial

Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma

Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial

Accumulation of an Endogenous Tryptophan-Derived Metabolite in Colorectal and Breast Cancers

Capabilities

Modalities